CN110003345A - A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda - Google Patents
A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda Download PDFInfo
- Publication number
- CN110003345A CN110003345A CN201910264564.9A CN201910264564A CN110003345A CN 110003345 A CN110003345 A CN 110003345A CN 201910264564 A CN201910264564 A CN 201910264564A CN 110003345 A CN110003345 A CN 110003345A
- Authority
- CN
- China
- Prior art keywords
- esed
- tat
- recombinant protein
- edwardsiella tarda
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Abstract
The invention discloses a kind of TAT-EseD recombinant protein of anti-Edwardsiella tarda and purposes, and the amino acid sequence of the TAT-EseD recombinant protein of anti-Edwardsiella tarda is as shown in SEQ ID NO.2.The TAT-EseD recombinant protein of anti-Edwardsiella tarda of the invention; TAT therein can carry EseD albumen and enter cell; enhance immune level of the EseD albumen as subunit vaccine; excitation EseD protein-specific cytotoxic lymphocyte reaction level is significantly improved, has higher, more permanent protecting effect for marine fish Edwardsiella tarda disease；Using Bacillus coli expression TAT-EseD recombinant protein, expression quantity is big, easy to operate, at low cost, and safety is good.
Description
Technical field
The invention belongs to gene biological field of engineering technology, and in particular to a kind of TAT-EseD of anti-Edwardsiella tarda
Recombinant protein and purposes.
Background technique
Caused by Edwardsiella tarda disease is mainly infected as Edwardsiella tarda, in each important economic fish
Such as turbot, Bastard halibut, Japanese eel and channel catfish have disease report.Disease outburst can cause a large amount of fish
Death causes serious economic loss to aquaculture.
Edwardsiella tarda disease without effective drug, mainly aims at prevention so far.But it is given birth in actual cultivation
In production, when disease occurs for cultured fishes, abuse, to misuse the case where fishing medicine very universal.Long-term drug abuse not only makes drug
Effect is restricted, and can also be induced pathogenic microorganism and be developed drug resistance, and " no medicine is available " is caused, and more seriously drug is being supported
Grow the further pollution of residual and breeding environment in animal body.As people are food-safe and the attention of Environmental security, eliminate
The disease-resistant technical research of aquatic products medicament residue hidden danger has been particularly important.Substitute of the vaccine as antibiotic, can make fish
The high attack for specifically resisting cause of disease of class, reduces the generation of fish diseases, preserves the ecological environment, it may be said that the exploitation of vaccines for fish and
Using with important and far-reaching meaning.
Vaccines for fish can be divided into inactivated vaccine, live bacterial vaccines (weak, attenuated vaccine) and base according to the difference of manufacture craft
Because of engineered vaccine.Inactivated vaccine and live bacterial vaccines are so that it is inactivated or is lost pathogenic using cause of disease is either physically or chemically handled
The advantages of power, this vaccine is to prepare simple, and immune protective effect is preferable, but not lasting there is immunity and virulence can return
The defects of multiple.With the development of biology techniques, the concern of the advantage of recombinant vaccine by everybody.Recombinant vaccine is
It is constituted using the method transformation or recombination pathogen gene acquisition recombinant protein, plasmid or intact pathogen of genetic engineering new
Type vaccine.
Animal body can be stimulated to generate antibody and responsiveness lymphocyte and in combination can cause specific immune response
Substance be referred to as antigen.As the bacterium of microbial antigen, structure is more complicated, can regard as by a variety of antigenic components
The complex of composition.
EseD molecular weight is about 21.1kD, is free of signal peptide, is hydrophilic protein, is that Edwardsiella tarda has significantly
Property protective effect one of antigen protein, can induce fish body generate specific antibody.TAT is AIDS virus (HIV-1)
Trans- transcriptional activation catalyst successfully carries polypeptide, fluorescent marker protein, DNA and small-molecule drug etc., realizes internal
Outer cross-film delivering.
But prevention marine fish Edwardsiella tarda is made in current not yet useful TAT and EseD preparation and reorganization albumen
Infect the report of vaccine.
Summary of the invention
The purpose of the present invention is overcome the deficiencies of the prior art and provide a kind of TAT-EseD weight of anti-Edwardsiella tarda
Histone.
A second object of the present invention is to provide a kind of TAT-EseD recombinant proteins for encoding anti-Edwardsiella tarda
Gene.
Egg is recombinated containing the TAT-EseD for encoding anti-Edwardsiella tarda third object of the present invention is to provide a kind of
The recombination engineering bacteria of white gene.
The TAT-EseD recombinant protein that fourth object of the present invention is to provide anti-Edwardsiella tarda is anti-slow in preparation
Purposes in slow tarda disease vaccine.
Technical solution of the present invention is summarized as follows:
A kind of TAT-EseD recombinant protein of anti-Edwardsiella tarda, the amino acid sequence of the recombinant protein such as SEQ
Shown in ID NO.2.
The gene of the TAT-EseD recombinant protein of anti-Edwardsiella tarda is encoded, the nucleotide sequence of the gene is such as
Shown in SEQ ID NO.1.
A kind of recombination engineering bacteria Arctic-Express containing said geneTM(DE3)/pCzn1-TAT-EseD,
It is that will convert prokaryotic hosts bacterium E.coli Arctic- containing the plasmid pCzn1-TAT-EseD of gene shown in SEQ ID NO.1
ExpressTM(DE3) it is obtained in competent cell.
The TAT-EseD recombinant protein of anti-Edwardsiella tarda is in the purposes for preparing anti-slow Edwardsiella vaccine.
Advantages of the present invention:
The TAT-EseD recombinant protein of anti-Edwardsiella tarda of the invention, TAT therein can carry EseD albumen
Into cell, enhance immune level of the EseD albumen as subunit vaccine, significantly improves excitation EseD protein-specific cell
Cytotoxic Lymphocytes reaction level has higher, more permanent protecting effect for marine fish Edwardsiella tarda disease；
Using Bacillus coli expression TAT-EseD recombinant protein, expression quantity is big, easy to operate, at low cost, and safety is good.
Detailed description of the invention
Fig. 1 is pCzn1-TAT-EseD expression vector establishment map.
Fig. 2 is TAT-EseD protein SDS-PAGE electrophoretogram.M, albumen Marker；1, non-induction expression protein；2, induction
Express albumen；3, albumen in supernatant；4, albumen in precipitating.
Specific embodiment
PCzn1 (commodity).
Prokaryotic hosts bacterium E. coli Arctic-ExpressTM(DE3) (commodity).
With reference to the accompanying drawing and specific embodiment is to the explanation of the affected step of the present invention.
All culture mediums and molecular biology manipulations method being related in embodiment are well known to those skilled in the art.
Molecular biology method involved in this experiment is conventional method, is familiar with by those skilled in the art.
The preparation of 1 recombination TAT-EseD of embodiment and expression plasmid building:
The gene order of Edwardsiella tarda EseD albumen is obtained from U.S.'s biotechnology center (NCBI) gene pool,
It is capable of the characteristic of amalgamation and expression according to the gene of nexin transduction domain peptide T AT coding and foreign protein genes, in EseD base
Because of the nucleotide sequence of 5 ' end connection TAT of sequence, name are as follows: TAT-EseD, sequence are nucleosides shown in SEQ ID NO.1
Acid sequence.
Artificial synthesized TAT-EseD gene, and be connected on pCzn1, building expression plasmid pCzn1-TAT-EseD is (as schemed
1)。
Using the plasmid containing target gene TAT-EseD as template, upstream and downstream primer is designed, sequence is respectively SEQ ID
Shown in NO.3 (upstream primer) and SEQ ID NO.4 (downstream primer), the target gene TAT-EseD of acquisition is cloned into carrier
Between I site Nde I and Xba of pCzn1, the plasmid pCzn1-TAT-EseD containing target gene can be obtained.
Embodiment 2
The building of Arctic-ExpressTM (DE3)/pCzn1-TAT-EseD recombination engineering bacteria
Plasmid conversion E. coli Arctic-ExpressTM (DE3) competence for taking 1 μ l embodiment 1 to obtain
Cell (is bought, PCR screening and identification goes out positive transformant, and resulting positive colony is to contain recombination by agilent company
The recombination engineering bacteria of TAT-EseD: Arctic-ExpressTM(DE3)/pCzn1-TAT-EseD.Referred to as: recombination work
Journey bacterium)
Embodiment 3
The expression and purification of genetic engineering recombinant protein TAT-EseD
(1) single colonie of recombination engineered strain is inoculated in the test tube of the 3ml LB culture solution containing 50 μ g/ml ammonia benzyls
In, 37 DEG C of 220rpm shakings are overnight.
(2) next day is inoculated in the 30ml LB culture solution of 50 μ g/ml ammonia benzyls by 1:100, and 37 DEG C of 220rpm shake 2h.So
1ml culture is taken out afterwards, and 10000g room temperature is centrifuged 2min, abandons supernatant.
(3) IPTG to final concentration of 0.5mM is added into remaining culture, 37 DEG C of 220rpm shake 4h, induce TAT-
The expression of EseD recombinant protein.
(4) by 4 DEG C of 6000g of culture bacterium solution after inducing expression, it is centrifuged 10min, it is slow that bacterial sediment is resuspended in 20ml cracking
In fliud flushing, ultrasonication (power 400W, work 4sec, interval 8sec, total 20min).
(5) 4 DEG C of 10000g of the cell pyrolysis liquid of ultrasonication are centrifuged 20min, collect precipitating.
(6) with dissolution buffer solution inclusion body, 4 DEG C are stood overnight；Room temperature, 15000rpm are centrifuged 15min；
(7) it is washed inclusion body 3 times using inclusion body cleaning solution；By precipitating 20ml Ni-IDA Binding-Buffer weight
After outstanding, ultrasonication (power 400W, work 4sec, interval 8sec, total 20min), 4 DEG C of 10000g are centrifuged 20min, take supernatant.
(8) low pressure chromatography system is utilized, supernatant is with 0.5ml/min flow velocity loading to Ni-IDA Binding-Buffer
The Ni-IDA-Sepharose CL-6B affinity column of pre-equilibration；It is flowed with Ni-IDA Binding-Buffer with 0.5ml/min
Speed is rinsed, until efflux OD280 value reaches baseline；With Ni-IDA Washing-Buffer (20mM Tris-HCl, 20mM miaow
Azoles, 0.15M NaCl, pH8.0) with the flushing of 1ml/min flow velocity, until efflux OD280 value reaches baseline；
(9) destination protein is eluted with 1ml/min flow velocity with Ni-IDA Elution-Buffer, collects efflux；It will be above-mentioned
The protein solution of collection is added in bag filter, carries out dialysed overnight using PBS (PH7.4), and what is purified has biology living
The genetic engineering recombinant protein TAT-EseD of property.Its sequence is shown in SEQ ID NO.2.
Embodiment 3 obtain TAT-EseD recombinant protein be subunit vaccine, as vaccine in use, by TAT-
EseD recombinant protein with PBS be resuspended to concentration be 400 μ g/ml, later with isometric QuickAntibodyTM(purchase is certainly for adjuvant
Beijing Bo Aolong Immune Technology Corp.) it mixes to get fish body is injected.
Immunological evaluation of the embodiment 4TAT-EseD recombinant protein as subunit vaccine
The healthy Paralichthys olivaceus of weight about 30g is from Tianjin seawater industrial culturing field.It is temporarily supported two weeks under laboratory condition.
Before on-test, several lefteye flounders are randomly selected, take liver and spleen kidney blood, Edwardsiella tarda is detected with PCR method, determines noninductive
Dye.The Bastard halibut of health is randomly divided into 6 groups, every group of 30 tail fishes.Every three groups are a parallel group, and group is respectively to inject TAT-
The test group (group1, group2 and group3) of EseD recombinant protein and inject PBS control group (control1,
Control2 and control3).Before injection, it is 400 μ g/ml, Zhi Houyu that TAT-EseD recombinant protein, which is resuspended with PBS to concentration,
Isometric QuickAntibodyTMAdjuvant (buys from Beijing Bo Aolong Immune Technology Corp.) mixing.Control group is PBS
It is mixed with isometric adjuvant.100 μ l vaccine suspensions are injected intraperitoneally in every tail fish.After two weeks, booster shots are immune primary for injection.Two
After secondary injecting immune, the 4th-six week took 3 tail Bastard halibuts from each injection group at random, and blood drawing carries out antibody titer measurement.Injecting immune
After six weeks, carry out challenge test.It attacks and counts the fish body death rate after poison daily, Computation immunity protective rate.
Injecting immune Bastard halibut twice after, the 4th-six week randomly selected 3 tail Bastard halibuts from every group, and tail portion blood drawing is resisted
Body titration.It the results are shown in Table 1.TAT-EseD recombinant protein can excite the immune response of fish body it can be seen from table, generate
Antibody.Inject PBS control group serum titer≤4.
1 serum titer statistical form of table
After injecting immune six weeks, carry out challenge test.The concentration of Edwardsiella tarda is 1 × 107Cfu/ml, every endnote
Penetrate 100 μ l.It attacks and counts the fish body death rate after poison daily, Computation immunity protective rate.It is shown in Table 2.Inject TAT-EseD group immunoprotection
Rate is higher than control group.
2 immune protective rate statistical form of table
Sequence table
<110>Tianjin Normal University
<120>the TAT-EseD recombinant protein and purposes of a kind of anti-Edwardsiella tarda
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 642
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
atgaatcaca aagtgcatca tcatcatcat catatgcgta aaaaacgtcg tcagcgtcgt 60
cgtggatcca tgacgactat cgacagcggc agccacggtg ttaacggcat taccccaccg 120
gacggccatc gttacgtttc acaggatcgc ggcggcgacg ccatcggcca gctgaatgag 180
ctgatggttc agcttggaga gctgtttggg aagctgcgcg atgtgctgcg ccagtatcaa 240
cagacacagc aaagcaacgc gttcaagatg caaaaaacag cgtatgacac ccgcgtggac 300
gccatcgata aagactttca ggccaagcag gcccaggcta tcgcgcaaat cctcggcggc 360
atcgcccaga ccgttggcgg ggcgttcgga gaagaggcgc ataccattag caacggcgtt 420
aacagcatga cgcaggggat tgtcggcgtc ggctatgtca atgacatgtc gcgtcagtcg 480
caggaggagc aggcgctgtc cgaatatcag cacggcctgg ccgagcagca gcttaagcgg 540
gcggatgaaa cgctggaaaa ggcgctcaag atctccggcg atctgcgcga gatactgacc 600
accctgaatc aggcccacga acgtatcgcc agcagcgtac gc 642
<210> 2
<211> 214
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 2
Met Asn His Lys Val His His His His His His Met Arg Lys Lys Arg
1 5 10 15
Arg Gln Arg Arg Arg Gly Ser Met Thr Thr Ile Asp Ser Gly Ser His
20 25 30
Gly Val Asn Gly Ile Thr Pro Pro Asp Gly His Arg Tyr Val Ser Gln
35 40 45
Asp Arg Gly Gly Asp Ala Ile Gly Gln Leu Asn Glu Leu Met Val Gln
50 55 60
Leu Gly Glu Leu Phe Gly Lys Leu Arg Asp Val Leu Arg Gln Tyr Gln
65 70 75 80
Gln Thr Gln Gln Ser Asn Ala Phe Lys Met Gln Lys Thr Ala Tyr Asp
85 90 95
Thr Arg Val Asp Ala Ile Asp Lys Asp Phe Gln Ala Lys Gln Ala Gln
100 105 110
Ala Ile Ala Gln Ile Leu Gly Gly Ile Ala Gln Thr Val Gly Gly Gly
115 120 125
Glu Glu Ala His Thr Ile Ser Asn Gly Val Asn Ser Met Thr Gln Gly
130 135 140
Ile Val Gly Val Gly Tyr Val Asn Asp Met Ser Arg Gln Ser Gln Glu
145 150 155 160
Glu Gln Ala Leu Ser Glu Tyr Gln His Gly Leu Ala Glu Gln Gln Leu
165 170 175
Lys Arg Ala Asp Glu Thr Leu Glu Lys Ala Leu Lys Ile Ser Gly Asp
180 185 190
Leu Arg Glu Ile Leu Thr Thr Leu Asn Gln Ala His Glu Arg Ile Ala
195 200 205
Ser Ser Val Arg Met Ser
210
<210> 3
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
atgaatcaca aagtgcatc 19
<210> 4
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
ttaggacatg cgtacgct 18
Claims (4)
1. a kind of TAT-EseD recombinant protein of anti-Edwardsiella tarda, it is characterized in that the ammonia of the recombinant protein TAT-EseD
Base acid sequence is as shown in SEQ ID NO.2.
2. the gene of the TAT-EseD recombinant protein of anti-Edwardsiella tarda described in claim 1 is encoded, it is characterized in that described
The nucleotide sequence of gene is as shown in SEQ ID NO.1.
3. a kind of recombination engineering bacteria Arctic-Express containing gene described in claim 2TM(DE3)/pCzn1-
TAT-EseD, it is characterized in that by prokaryotic hosts bacterium is converted containing the plasmid pCzn1-TAT-EseD of gene shown in SEQ ID NO.1
E.coli Arctic-ExpressTM(DE3) it is obtained in competent cell.
4. the TAT-EseD recombinant protein of the anti-Edwardsiella tarda of claim 1 is preparing anti-slow Edwardsiella vaccine
In purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910264564.9A CN110003345A (en) | 2019-04-03 | 2019-04-03 | A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910264564.9A CN110003345A (en) | 2019-04-03 | 2019-04-03 | A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110003345A true CN110003345A (en) | 2019-07-12 |
Family
ID=67169566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910264564.9A Pending CN110003345A (en) | 2019-04-03 | 2019-04-03 | A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110003345A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481185A (en) * | 2020-12-10 | 2021-03-12 | 中国科学院水生生物研究所 | Construction and application of soaking vaccine strain for preventing yellow catfish head cracking disease |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102703483A (en) * | 2012-06-08 | 2012-10-03 | 武汉凯肽来生物科技有限公司 | Recombinant oral protein TAT-GH of tilapia, preparation method for recombinant oral protein TAT-GH and application of recombinant oral protein TAT-GH |
| CN103014051A (en) * | 2012-11-27 | 2013-04-03 | 华东理工大学 | Multiple-potency live vaccine for fish and application thereof |
| CN103690942A (en) * | 2013-12-20 | 2014-04-02 | 中国水产科学研究院黄海水产研究所 | Edwardsiella tarda subunit vaccine, and preparation and application thereof |
| US20140308262A1 (en) * | 2013-04-15 | 2014-10-16 | BioBlast Pharma Ltd. | Mitochondrial Proteins Constructs and Uses Thereof |
-
2019
- 2019-04-03 CN CN201910264564.9A patent/CN110003345A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102703483A (en) * | 2012-06-08 | 2012-10-03 | 武汉凯肽来生物科技有限公司 | Recombinant oral protein TAT-GH of tilapia, preparation method for recombinant oral protein TAT-GH and application of recombinant oral protein TAT-GH |
| CN103014051A (en) * | 2012-11-27 | 2013-04-03 | 华东理工大学 | Multiple-potency live vaccine for fish and application thereof |
| US20140308262A1 (en) * | 2013-04-15 | 2014-10-16 | BioBlast Pharma Ltd. | Mitochondrial Proteins Constructs and Uses Thereof |
| CN103690942A (en) * | 2013-12-20 | 2014-04-02 | 中国水产科学研究院黄海水产研究所 | Edwardsiella tarda subunit vaccine, and preparation and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| MAYUMI HASHIMOTO等: "S Phase-preferential Cre-recombination in mammalian cells revealed by HIV-TAT-PTD-mediated protein transduction", 《THE JOURNAL OF BIOCHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481185A (en) * | 2020-12-10 | 2021-03-12 | 中国科学院水生生物研究所 | Construction and application of soaking vaccine strain for preventing yellow catfish head cracking disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hao et al. | Display of GCRV vp7 protein on the surface of Escherichia coli and its immunoprotective effects in grass carp (Ctenopharyngodon idella) | |
| CN101883580B (en) | Subunit vaccine for aquaculture | |
| CN104628865B (en) | A kind of pseudo- mad dog epitope polypeptide recombinant vaccine | |
| CN104628871B (en) | A kind of preparation for recombinating bursal disease protein engineering vaccine | |
| CN102168088A (en) | T cell immunogen gene TI and applications thereof in foot-and-mouth disease protein subunit vaccine and inactivated vaccine | |
| CN102580074B (en) | Riemerella anatipestifer-escherichia coli outer membrane protein bivalent vaccine and preparation method thereof | |
| CN110003345A (en) | A kind of the TAT-EseD recombinant protein and purposes of anti-Edwardsiella tarda | |
| CN103694321A (en) | Staphylococcus aureus mSEB mutant and preparation method and application thereof | |
| CN104250304B (en) | The vaccine combination of a kind of fusion protein and its coding and application | |
| CN105906717A (en) | Preparation method and application of Brucella multi-epitope fusion protein vaccine | |
| CN110746496B (en) | PAL recombinant protein of Acinetobacter baumannii, encoding gene thereof and application of PAL recombinant protein and encoding gene | |
| CN103260644A (en) | Parapoxvirus vectors containing rabies virus antigen | |
| CN1748791B (en) | Haemorrhagic E, coli 0157:H7 vaccine for human and livestock prevention and preparing method | |
| CN114716571B (en) | Metallothionein 3 and Omp19 fused recombinant protein and application thereof | |
| CN108410784B (en) | Streptococcus suis delta CPS/SsnA-mSly (P353L) -SC19 engineering bacteria and application thereof in vaccines | |
| CN106117365A (en) | Anti-streptococcus suis is sick and has the active fusion protein of autoimmune and preparation thereof and application | |
| CN104072590B (en) | A kind of hitchens and Hansen antigen combination and its application | |
| CN102406929A (en) | Co-expressed molecular adjuvant enhanced divalent foot and mouth disease protein engineering vaccine | |
| CN112646046B (en) | Multi-epitope fusion protein for preventing pseudomonas aeruginosa infection and coding gene, expression vector and application thereof | |
| WO2014200325A2 (en) | Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis | |
| CN112279925B (en) | Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof | |
| CN104248754A (en) | Streptococcus suis vaccine composition, and preparation method and application thereof | |
| CN110028559B (en) | Pseudomonas aeruginosa vaccine recombinant protein, coding gene thereof and application thereof | |
| CN109879971A (en) | A kind of the TAT-CP recombinant protein and purposes of anti-β Nodavirus | |
| CN102993310A (en) | Fusion protein of IBD (Infectious Bursal Disease) VP2 and IL (Interleukin)-2 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190712 |